10x Genomics EBIT margin
Was ist das EBIT margin von 10x Genomics?
EBIT margin von 10x Genomics, Inc. ist -36.92%
Was ist die Definition von EBIT margin?
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
EBIT margin von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 10x Genomics
Was macht 10x Genomics?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Unternehmen mit ebit margin ähnlich 10x Genomics
- GJ Culture US hat EBIT margin von -37.18%
- DEAG Deutsche Entertainment Aktiengesellschaft hat EBIT margin von -37.12%
- DEAG Deutsche Entertainment Aktiengesellschaft hat EBIT margin von -37.12%
- SiteMinder hat EBIT margin von -37.11%
- Medallia Inc hat EBIT margin von -37.03%
- ForeScout Technologies Inc hat EBIT margin von -37.01%
- 10x Genomics hat EBIT margin von -36.92%
- House of Control AS hat EBIT margin von -36.91%
- East 33 Ltd hat EBIT margin von -36.90%
- StartEngine Crowdfunding hat EBIT margin von -36.86%
- RMG Alloy Steel hat EBIT margin von -36.78%
- Indus hat EBIT margin von -36.66%
- Asana hat EBIT margin von -36.62%